Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 3, 2011, Pages 543-550

  Bewick, Mary A ^a   Lafrenie, Robert M ^a,b   Conlon, Michael S C ^a  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

Metastatic breast cancer; Nucleotide excision repair; Single nucleotide polymorphisms; Survival

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MITOXANTRONE; PACLITAXEL; THIOTEPA; VINBLASTINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; EXCISION REPAIR; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL RATE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN; YOUNG ADULT;

EID: 79954432909     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0915-7     Document Type: Article

References (53)

1. Abdel-Rahman SZ, El-Zein RA (2000) The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159:63-71
2. Affatato AA, Wolfe KJ, Lopez MS et al (2004) Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. Environ Mol Mutagen 44:65-73 (Pubitemid 38982073)
3. Altaha R, Liang X, Yu JJ et al (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14:959-970
4. Ambrosone CB, Ahn J, Singh KK et al (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 65:1105-1111 (Pubitemid 40216474)
5. Ambrosone CB, Tian C, Ahn J et al (2006) Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 8: R40
6. Andersson BS, Sadeghi T, Siciliano MJ et al (1996) Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 38:406-416 (Pubitemid 26281077)
7. Au WW, Salama SA, Sierra-Torres CH (2003) Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111:1843-1850 (Pubitemid 37526965)
8. Au WW, Navasumrit P, Ruchirawat M (2004) Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health 207:301-313 (Pubitemid 39222724)
9. Azuma K, Komohara Y, Sasada T et al (2007) Excision repair crosscomplementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336-1343 (Pubitemid 47241754)
10. Benhamou S, Sarasin A (2005) ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 161:1-14 (Pubitemid 40053274)
11. Bewick MA, Conlon MS, Lafrenie RM (2006) Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24:5645-5651 (Pubitemid 46631304)
12. Bewick MA, Conlon MS, Lafrenie RM (2008) Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 111:93-101 (Pubitemid 352009233)
13. Booton R, Ward T, Heighway J et al (2006) Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106:2421-2427 (Pubitemid 43787666)
14. Bradbury PA, Kulke MH, Heist RS et al (2009) Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 19:613-625
15. Carles J, Monzo M, Amat M et al (2006) Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 66:1022-1030 (Pubitemid 44633517)
16. Caronia D, Patino-Garcia A, Milne RL et al (2009) Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 9:347-353
17. Chen P, Wiencke J, Aldape K et al (2000) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9:843-847 (Pubitemid 30660059)
18. Chew HK, Doroshow JH, Frankel P et al (2009) Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 27:2163-2169
19. Duell EJ, Wiencke JK, Cheng TJ et al (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965-971 (Pubitemid 30265141)
20. Durr FE, Wallace RE & Citarella RV (1983) Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 10 Suppl B: 3-11 (Pubitemid 14150764)
21. Farquhar CM, Marjoribanks J, Lethaby A et al (2007) High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 33:325-337 (Pubitemid 46778206)
22. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22
23. Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced nonsmall-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601 (Pubitemid 41103746)
24. Handra-Luca A, Hernandez J, Mountzios G et al (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13:3855-3859 (Pubitemid 47037591)
25. Herrera M, Dominguez G, Garcia JM et al (2009) Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay. Clin Cancer Res 15:5466-5472
26. Hou SM, Falt S, Angelini S et al (2002) The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 23:599-603 (Pubitemid 34498497)
27. Hutsell SQ, Sancar A (2005) Nucleotide excision repair, oxidative damage, DNA sequence polymorphisms, and cancer treatment. Clin Cancer Res 11:1355-1357 (Pubitemid 40315212)
28. Kamikozuru H, Kuramochi H, Hayashi K et al (2008) ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 32:1091-1096
29. Le Morvan V, Bellott R, Moisan F et al (2006) Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-avis the NCI-60 panel. Pharmacogenomics 7:843-852 (Pubitemid 44446735)
30. Le Morvan V, Smith D, Laurand A et al (2007) Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8:1693-1703
31. Lee HW, Han JH, Kim JH et al. (2007) Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer
32. Lin J, Swan GE, Shields PG et al (2007) Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotypephenotype correlation. Cancer Epidemiol Biomarkers Prev 16:2065-2071 (Pubitemid 47621181)
33. Lunn RM, Helzlsouer KJ, Parshad R et al (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21:551-555 (Pubitemid 30214005)
34. Matullo G, Palli D, Peluso M et al (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32) P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22:1437-1445 (Pubitemid 32898701)
35. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184 (Pubitemid 41258223)
36. Nagle CM, Chenevix-Trench G, Spurdle AB et al (2007) The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 43:283-290 (Pubitemid 46123985)
37. Nowell SA, Ahn J, Rae JM et al (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258 (Pubitemid 40903087)
38. Petty WJ, Knight SN, Mosley L et al (2007) A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. J Thorac Oncol 2:197-202 (Pubitemid 47181324)
39. Quintela-Fandino M, Hitt R, Medina PP et al (2006) DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24:4333-4339 (Pubitemid 46630792)
40. Reed E (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11:6100-6102 (Pubitemid 41262934)
41. Reed E, Kohn EC, Sarosy G et al (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22:90-96
42. Rzeszowska-Wolny J, Polanska J, Pietrowska M et al (2005) Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res 164:132-140 (Pubitemid 41045593)
43. Simon GR, Ismail-Khan R, Bepler G (2007) Nuclear excision repairbased personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39:1318-1328 (Pubitemid 47031049)
44. Spitz MR, Wu X, Wang Y et al (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354-1357 (Pubitemid 34292555)
45. Suk R, Gurubhagavatula S, Park S et al (2005) Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11:1534-1538 (Pubitemid 40315237)
46. Vodicka P, Kumar R, Stetina R et al (2004) Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25:757-763 (Pubitemid 38618528)
47. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320 (Pubitemid 41130944)
48. Wolfe KJ, Wickliffe JK, Hill CE et al (2007) Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics 17:897-905 (Pubitemid 350293790)
49. Wu X, Gu J, Wu TT et al (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789-3798 (Pubitemid 46628477)
50. Wu X, Lu C, Ye Y et al (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18:955-965
51. Zhang CC, Yang JM, Bash-Babula J et al (1999) DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubuleassociated protein 4. Cancer Res 59:3663-3670 (Pubitemid 29381870)
52. Zhang Y, Rohde LH, Wu H (2009) Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair. Curr Genomics 10:250-258
53. Zhou W, Gurubhagavatula S, Liu G et al (2004) Excision repair crosscomplementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939-4943 (Pubitemid 39099767)